Third Harmonic Bio announces CSO Ray’s transition to SA, CFO Ho to depart

Third Harmonic Bio announced the transition of Adrian Ray, Ph.D., from Chief Scientific Officer, CSO, to Scientific Advisor, SA, effective November 1, 2023. In his new role, Dr. Ray will continue support the company’s Investigational New Drug, IND, application for THB335, which is expected to be filed during the first half of 2024. Additionally, the company announced that Robert Ho, Chief Financial Officer, CFO, will depart the organization on November 10, 2023. The company has initiated executive searches for their successors.